Zenas BioPharma (ZBIO) Enterprise Value (2023 - 2026)

Zenas BioPharma's Enterprise Value history runs 4 years deep, the most recent figure standing at -$717.2 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 66.78% year-over-year to -$717.2 million in Q1 2026; TTM through Mar 2026 was -$717.2 million, a 66.78% decrease from a year earlier, with the FY2025 full-year figure at -$343.2 million, up 2.16% from the prior year.
• Enterprise Value fell to -$717.2 million in Q1 2026 per ZBIO's latest filing, from -$343.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$37.2 million in Q1 2024 and bottomed at -$717.2 million in Q1 2026.
• The 4-year median for Enterprise Value is -$343.2 million (2025), against an average of -$300.2 million.
• Biggest YoY gain for Enterprise Value was 2.16% in 2025; the steepest drop was 1054.74% in 2025.
• Year by year, Enterprise Value stood at -$56.9 million in 2023, then sank by 516.93% to -$350.8 million in 2024, then advanced by 2.16% to -$343.2 million in 2025, then tumbled by 108.98% to -$717.2 million in 2026.
• Per Business Quant, the three latest ZBIO Enterprise Value figures stand at -$717.2 million (Q1 2026), -$343.2 million (Q4 2025), and -$476.9 million (Q3 2025).